Half a decade of data on the second generation iStent inject has shown a significant reduction in intraocular pressure (IOP) and medication burden in glaucoma patients. Read more
ASX-listed ophthalmic technology company Nova Eye Medical expects more cataract surgeons and comprehensive ophthalmologists to uptake its glaucoma canaloplasty procedure, with the launch of its improved iTrack device in select Europe and Asia Pacific markets this week. Read more
Australian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no significant difference in intraocular pressure (IOP) outcomes but a potential greater reduction in medication use in one group. Read more
Glaucoma affects an estimated 300,000 Australians but half of them don’t know it. Early detection is considered vital to prevent irreversible vision loss and blindness. Read more
A pioneering solution for assessing glaucoma risk in clinical settings is closer to commercialisation with the support of a $304,000 state government seed grant. Read more
Despite modest sales growth in the first half of the current financial year, ASX-listed Nova Eye Medical believes it’s poised for stronger returns from its glaucoma portfolio with a revamped canaloplasty device, making the technology more accessible to a broader base of ophthalmologists. Read more
Glaucoma surgeon Dr Nathan Kerr has performed Victoria’s first procedure with the PRESERFLO MicroShunt, first approved by the Therapeutic Goods Administration (TGA) in mid-2021. Read more
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of visual field loss by 47% versus cataract surgery alone. Read more
When it comes to the treatment of glaucoma, there is growing evidence to suggest that the ability to re-establish the natural flow of aqueous humour plays a critical role not only in reducing IOP, but also in preserving the health of the corneal endothelium, says US ophthalmologist DR DAVID LUBECK.
MIGS has triggered a shift in the glaucoma paradigm, enabling surgical intervention that bridges the gap between medical management and invasive surgery. While much of the focus has been on stent-based procedures, DR NATHAN KERR says surgeons should be excited by an entirely different approach by Australia’s Nova Eye Medical.